dendreon ranked highest in sales growth, page-16

Agent86

Your earlier post stated a tie-up with DNDN would make perfect sense. Perhaps for DNDN, but not for PRR shareholders.

You made reference numerous times to "Competitors". PRR and DNDN are not competitors. Sure they are both companies whose primary product technology is in the field of immunotherapy for cancer treatment, but they are primarily targeting different cancers (albeit with some potential overlap, way downstream).

The two companies can happily co-exist. I'm not saying a takeover wont happen, just that it would be in the best interests of shareholders for the company to get well down the track before it does. At least to FDA approval but preferably into commercialisation.